权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Drug combination nanoparticles for advanced treatment of metastatic TNBC

用于晚期治疗转移性 TNBC 的药物组合纳米颗粒

基本信息

批准号：
10648912
负责人：
Qingxin Mu
金额：
$ 19.98万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-03-10 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10648912
关键词：
Animal Model Antibody-drug conjugates Antimetabolites Behavior Binding Biological Markers Breast Cancer Cell Breast Cancer Model Breast Cancer Treatment Cause of Death Cell Surface Receptors Cells Clinic Clinical Combination Drug Therapy Combined Modality Therapy Development Disease Disseminated Malignant Neoplasm Distant Dose Drug Combinations Drug Compounding Drug Delivery Systems Drug Kinetics Drug Synergism Drug Targeting ENG gene Eligibility Determination Endoglin Formulation Future Goals Guidelines Half-Life Human Image Immune checkpoint inhibitor Immunocompetent Immunotherapeutic agent Immunotherapy In Vitro Intercellular adhesion molecule 1 Life Extension Ligands Lipids Lung Membrane Glycoproteins Messenger RNA Metastatic Neoplasm to the Lung Metastatic breast cancer Micrometastasis Modeling Monitor Mus Myeloid-derived suppressor cells Neoplasm Metastasis New Agents Outcome PD-1/PD-L1 PDL1 inhibitors Paclitaxel Patients Peptides Pharmaceutical Preparations Plasma Population Primary Neoplasm Prognosis Property Publishing Regimen Reporting Site Spleen Survival Rate Technology Testing Therapeutic Time Tissues Toxic effect Treatment Efficacy Treatment outcome Up-Regulation Woman Work anti-PD-L1 therapy anti-PD1 antibodies cancer cell cancer immunotherapy cellular targeting checkpoint therapy chemotherapy clinical translation dosage gemcitabine immunoregulation improved improved outcome in vivo indexing innovation insight lipid nanoparticle malignant breast neoplasm mortality nanoformulation nanoparticle novel drug combination novel therapeutics pembrolizumab peptide drug programmed cell death ligand 1 receptor receptor expression response synergism systemic toxicity targeted treatment taxane therapeutic target therapy outcome treatment effect triple-negative invasive breast carcinoma tumor tumor growth uptake

项目摘要

Project Description Triple negative breast cancer (TNBC) is the most challenging subtype to treat among all breast cancer cases due to lack of cell surface receptors. Patients with metastatic TNBC have median overall survival of only 13.3 months with treatment. Newly approved immune checkpoint inhibitors such as PD-1 antibody only extend the survival by 2-4 months when used with chemotherapy, and the efficacy highly relies on expression of targets such as PD-L1 in tumors. Despite new treatment options, metastatic TNBC is predominantly treated by highly potent chemotherapy, with combination therapy being advantageous over single agents regarding response rate and overall survival. However, the drugs in combination chemotherapy have distinct physicochemical properties that hinders formulation into single dosage; their distinct pharmacokinetic behavior hinders the in vivo synergism. Furthermore, these drugs are non-specific to cancer cells and often show systemic toxicity. Our long-term goal is to develop advanced and well-characterized drug delivery approaches to improve treatment outcomes of drugs and drug combinations. In this project, we propose a dual-drug loaded dual-peptide ligand incorporated drug combination nanoparticle (DCNP) approach for targeting and inhibition of metastatic TNBC. The lipid-based DCNP leverage on effective gemcitabine and paclitaxel combination in clinic to deliver both drugs in prolonged and synchronized manner. Through incorporation of two peptide ligands that targets TNBC cells (through ICAM- 1) and tumor vasculature (through endoglin), the DCNP could target both primary tumor and metastasis for enhanced chemotherapy. Furthermore, both drugs are reported to upregulate PD-L1 and reduce population of myeloid derived suppressor cells (MDSCs) in the tumor. These effects can sensitize TNBC cells for PD-1/PD-L1 therapy. The DCNPs that synchronize and co-deliver both drugs may further augment such effects thus generate improved chemoimmuno therapeutic outcomes. The objectives of this project are to validate the concepts of improved targeting and chemotherapy of metastatic TNBC with a dual-targeting DCNP approach and enhanced combination therapy with immune checkpoint inhibitors. In Aim 1, we will prepare ligands-incorporated DCNPs with high drug loading, proper size, and good stability, and test their cellular binding and efficacy, and effects on cancer cell expression of PD-L1. In Aim 2, we will validate enhanced in vivo targeting efficiency with the dual- ligand strategy and correlate it with expression levels of receptors and evaluate inhibition of primary tumor and metastasis with monitoring of survival. In Aim 3, we will assess the upregulation of PD-L1 and reduction of MDSCs by the DCNPs and carry out a pilot survival study with a chemoimmuno combination regimen. If successful, this targeted drug combination strategy could substantially improve the treatment of metastatic TNBC. Through tuning composition and targeting ligands, this highly translatable nanoformulation technology can be potentially used for existing and future drug combinations to treat various metastatic cancers.

项目说明三阴性乳腺癌(TNBC)是所有乳腺癌病例中最具挑战性的亚型由于缺乏细胞表面受体。转移性TNBC患者的中位总生存期仅为13.3 接受了数月的治疗。新批准的免疫检查点抑制剂，如PD-1抗体，仅延长了当与化疗一起使用时，生存期为2-4个月，其疗效高度依赖于靶点的表达如肿瘤中的PD-L1。尽管有新的治疗选择，转移性TNBC的治疗主要是通过高度强效化疗，联合治疗在有效率方面优于单一药物以及总体存活率。然而，联合化疗中的药物具有不同的物理化学性质这阻碍了制剂的单次给药；它们独特的药代动力学行为阻碍了体内的协同作用。此外，这些药物对癌细胞没有特异性，经常表现出全身毒性。我们的长期目标是开发先进的和具有良好特性的药物输送方法，以改善药物的治疗结果以及药物组合。在本项目中，我们提出了一种双药载药的双肽配基药物。联合纳米颗粒(DCNP)靶向和抑制转移的TNBC。以脂质为基础的 DCNP利用吉西他滨和紫杉醇的有效联合在临床上延长这两种药物的给药时间和同步的方式。通过掺入两个靶向TNBC细胞的多肽配体(通过ICAM- 1)和肿瘤血管系统(通过endoglin)，DCNP可以靶向原发肿瘤和转移瘤强化化疗。此外，据报道，这两种药物都能上调PD-L1并减少糖尿病患者的数量。肿瘤中的髓系抑制细胞(MDSCs)。这些效应可使TNBC细胞对PD-1/PD-L1敏感心理治疗。使两种药物同步并共同递送的DCNP可能进一步增强由此产生的效果改善了化疗免疫治疗的结果。该项目的目标是验证以下概念双靶向DCNP和增强型靶向治疗转移性TNBC的疗效观察与免疫检查点抑制剂的联合治疗。在目标1中，我们将制备配体结合的DCNPs 载药量高，大小适中，稳定性好，并测试其细胞结合和疗效，以及对癌细胞中PD-L1的表达。在目标2中，我们将验证增强的体内靶向效率与双重- 配体策略，并将其与受体的表达水平相关联，评估对原发肿瘤和转移和生存监测。在目标3中，我们将评估PD-L1上调和减少通过DCNP移植MDSCs，并使用化学免疫联合方案进行中试生存研究。如果如果成功，这种靶向药物联合策略可以显著改善转移性TNBC的治疗。通过调整成分和靶向配体，这种高度可翻译的纳米制剂技术可以可能用于现有和未来治疗各种转移性癌症的药物组合。